Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria

This study has been terminated.
University of Oxford
Information provided by (Responsible Party):
Dilaforette AB Identifier:
First received: September 23, 2011
Last updated: August 18, 2014
Last verified: August 2014

The purpose of this study is to determine the tolerability and pharmacokinetics of Sevuparin/DF02 when administered as an i.v. infusion in combination with Malanil® (atovaquone/proguanil) as anti-malarial treatment in subjects affected with uncomplicated malaria. The study will also assess the potential of Sevupatin/DF02 to reduce infected erythrocyte sequestration and rosette formation.

The study consists of a dose escalation part (part 1) followed by an open labelled, randomized comparison of treatment with Sevuparin/DF02 and Malanil® versus Malanil® alone (part 2).

Condition Intervention Phase
Malaria, Falciparum
Drug: Sevuparin sodium + atovaquone/proquanil
Drug: atovaquone/proquanil
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria

Resource links provided by NLM:

Further study details as provided by Dilaforette AB:

Primary Outcome Measures:
  • Dose limiting toxicities according to specified criteria [ Time Frame: During treatment and 14 days post treatment follow-up. ] [ Designated as safety issue: Yes ]
  • Area under the curve of late stage peripheral blood parasitemia over time (Part 2). [ Time Frame: 72 hours ] [ Designated as safety issue: No ]

Enrollment: 53
Study Start Date: September 2011
Study Completion Date: January 2014
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sevuparin/DF02
Sevuparin/DF02 plus anti-malarial regimen (Malanil®)
Drug: Sevuparin sodium + atovaquone/proquanil
Sevuparin 4 times per day and malanil according to label
Active Comparator: Control
Anti-malarial regimen (Malanil®) alone
Drug: atovaquone/proquanil
malanil according to label


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Presence of acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with asexual forms of a single species (P. falciparum)
  • Counts of asexual forms of P. falciparum: 10 000- 100 000/ul with or without gametocytaemia
  • Presence of fever defined as > 38°C tympanic temperature or a history of fever within the last 24 hours

Exclusion Criteria:

  • Mixed infection with other Plasmodium species
  • Any criteria of severe or complicated malaria as defined by the WHO, 2010
  • Use of high doses aspirin (more than 100 mg/day) or dual anti-platelet therapy or use of heparin,Low Molecular Weight Heparin (LMWH) or warfarin
  • Presence of significant anemia as defined by Hb <8 g/dL or Hct < 25%
  • A platelet count < 50,000/μL
  • Presence of febrile conditions caused by diseases other than malaria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01442168

Mae Ramat Hospital
Mae Ramat, Tak province, Thailand
Maesot General hospital
Mae Sot, Tak Province, Thailand
Hospital for Tropical Diseases
Bangkok, Thailand
Sponsors and Collaborators
Dilaforette AB
University of Oxford
Study Director: Anna Leitgeb, PhD Dilaforette AB
  More Information

No publications provided

Responsible Party: Dilaforette AB Identifier: NCT01442168     History of Changes
Other Study ID Numbers: Sevuparin/DF02_TSM02
Study First Received: September 23, 2011
Last Updated: August 18, 2014
Health Authority: Thailand: Ministry of Public Health

Keywords provided by Dilaforette AB:
Uncomplicated Falciparum Malaria
Plasmodium falciparum
Antimalarial treatment
Adjuvant therapy
Peripheral blood parasitemia
Rosette formation
Maximum tolerated dose

Additional relevant MeSH terms:
Malaria, Falciparum
Parasitic Diseases
Protozoan Infections
Anti-Infective Agents
Antiparasitic Agents
Antiprotozoal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 27, 2014